ViroMed’s VM202 emerging as blockbuster medicine

Published: 2008-12-01 06:31:00
Updated: 2008-12-01 06:31:00
ViroMed said on November 28 that the phase I study results of VM202, a gene-based medicine for cardiovascular disease (CVD) were presented in the Seoul National University Hospital’s clinical center.

The clinical results consolidated three clinical trials conducted in the US, China and Korea.
...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.